Translate page

Education

Research

    CML publications

    Please find below a selection of interesting articles on CML from peer-reviewed journals. Recent publications include:

    Clinical CML papers

    Scientific CML papers

    More CML Publications 2025

    Clinical Publications Scientific Publications
    April 2025
    Chronic myeloid leukemia Treatment (PDQ): Patient Version
    PDQ Adult Treatment Editorial Board, April 2025 – open access publication
    KF1601, a dual inhibitor of BCR::ABL1 and FLT3, overcomes drug resistance in FLT(+) blast phase chronic myeloid leukemia
    Kwon HJ et al. Mol Cancer, April 2025 – open access publication
    Molecular response with Ascminib 20 mg QD in a patient intolerant to multiple TKIs
    Stuckey R et al. Ann Hematol, April 2025
    (epub ahead of print)
     – open access publication
    High-throughput drug screening identifies SMAC mimetics as enhancers of NK-cell cytotoxicity in chronic myeloid leukemia
    Nygrén P et al. Blood, April 2025
    – open access publication
      A network-based approach to overcome BCR::ABL1-independent resistance in chronic myeloid leukemia
    Bica V et al. Cell Commun Signal, April 2025 – open access publication
      The impact of the solute carrier gene superfamily polymorphisms on tyrosine kinase inhibitors responses among chronic myeloid leukemia: A meta-analysis
    Thuy VT et al. Leuk Res, April 2025
     

    Dysregulation of sphingolipid metabolism contributes to the pathogenesis of chronic myeloid leukemia
    Xie Y et al. Cell Death Dis, April 2025
    – open access publication 

    March 2025
    Twin pregnancy during treatment with asciminib for chronic myeloid leukemia – a care report
    Gutierrez de Moraes Pereira GBBM. Ann Hematol, March 2025
    (epub ahead of print)
    – open access publication
    PTBP2 promotes cell survival and autophagy in chronic myeloid leukemia by stabilizing BNIP3
    Barik B et al. Cell Death Dis, March 2025
    – open access publication
    Nilotinib induced diabetes in Japanese patients with chronic myeloid leukemia
    Iwamoto Y et al. Intern Med, March 2025
    – open access publication
    Different in vitro models of chronic myeloid leukemia show different characteristics: Biological replicates are not biologically equivalent
    Cavalleri A et al. Cell Biol Int, March 2025 (epub ahead of print)
    – open access publication
    Severe acute cutaneous-only graft-versus-host disease after late relapse of chronic myeloid leukemia and ultraviolet B photography
    Beeler JS et al. Haematologica, March 2025 – open access publication
    Comprehensive analysis of tyrosine kinase inhibitor domain mutations and imatinib resistance in chronic myeloid leukemia patients
    Dhangar S et al. Leuk Res, March 2025 (epub ahead of print)
    Alternative routes of drug administration: Exposure of imatinib using different formulations
    Fiebrich-Westra HB et al. Cancer Chemother Pharmacol, March 2025
    Selective translational control by PABPC1 phase separation regulates blast crisis and therapy resistance in chronic myeloid leukemia
    Sun C et al. Nat Cell Biol, March 2025 (epub ahead of print)
    Evaluation of leukemic stem cell (CD26+) in chronic myeloid leukemia patients with different molecular response and in treatment-free remission
    Camado MF et al. Clin Exp Med, March 2025
    – open access publication
    Asciminib: The tyrosine kinase inhibitor with a unique mode of action - Review
    Jain AG and Cortes JE. Expert Opin Pharmacother, March 2025 (epub ahead of print) 
    A Gremlin 1-expressing splenic niche cell population restrains chronic myeloid leukemia by antagonizing the BMP pathway
    Wang J et al. Nat Cancer, March 2025
    (epub ahead of print)
    Considerations on the dose and schedule of tyrosine kinase inhibitors for chronic myeloid leukemia: Does dose matter?
    Dalgetty M and Cortes JE. Blood, March 2025
    (epub ahead of print) 
      Imatinib and the dawn of precision cancer medicine
    Druker BJ. Nat Med, March 2025 
      Living, not just surviving with CML – quality of life to the front of the line
    Lipton JH and Rea D. Leukemia, March 2025
    (epub ahead of print) 
      Chronic myeloid leukemia: A review
    Jabbour E and Kantarjian H. JAMA, March 2025
    (epub ahead of print)  
      Association between the profile of patients with chronic myeloid leukemia and adherence to tyrosine kinase inhibitors
    Rodrigues Moreira P et al. J Oncol Pharm Pract,
    March 2025 (epub ahead of print)
      Do we need another TKI for chronic myeloid leukemia?
    Hjorth-Hansen H. Lancet Haematol, March 2025
      Switching TKIs during CML therapy is frequent, mostly driven by intolerance, and does not affect survival: a prospective Quebec registry study
    Busque L et al. Blood Cancer J, March 2025
    – open access publication
    February 2025
    Patient-reported outcomes in Chinese patients with chronic myeloid leukemia receiving Olverembatinib: Quality of life matters!
    Eşkazan AE. Cancer, February 2025
    Autophagy and Cancer: Insights into molecular mechanisms and therapeutic approaches for chronic myeloid leukemia – Review
    Kausar MA et al. Biomolecules, February 2025 – open access publication
    Novel treatment strategies for chronic myeloid leukemia – Review
    Cruz-Rodriguez N and Deininger MW. Blood, February 2025
    CAR-macrophages targets CD26 to eliminate chronic myeloid leukemia stem cells
    Guoyun J et al. Exp Hematol, February 2025 – open access publication
    Long-term outcomes of tyrosine kinase inhibitors in chronic myeloid leukemia – Review
    Guilhot F and Hehlmann R. Blood, February 2025
    MDM2 inhibitors induce apoptosis by suppressing MDM2 and enhancing p53, Box, Puma and Noxa expression levels in imatinib-resistant chronic myeloid leukemia cells
    Kimura A et al. Biomed Rep, February 2025 – open access publication
    Unrelated bone marrow transplantation for CML after liver transplantation
    Watanabe M et al. Intern Med, February 2025
    (epub ahead of print) 
    – open access publication
    MiR-142 deficit in T-cells during blast crisis promotes chronic myeloid leukemia immune escape
    Chen F et al. Nat Commun, February 2025 – open access publication
    Treatment-emergent resistance to asciminib in chronic myeloid leukemia patients due to myristoyl-binding pocket-mutant of BCR::ABL1/A337V can be effectively overcome with dasatinib treatment
    Batar P et al. Curr Oncol, February 2025
    – open access publication
    Low-dose bee venom as a potential target against human chronic myeloid leukemia cells
    Halici H et al. Protein J, February 2025
    (epub ahead of print)
    A CML patient carrying BCR::ABL1 splicing variant did not experience blast crisis for 15 years without responding to various TKIs
    Nakamura F et al. Intern Med, February 2025 – open access publication
    Circumventing imatinib resistance in chronic myeloid leukemia: Novel Telmirsatan-based cell death modulators with improved activity and stability
    Gebhart M et al. Eur J Med Chem, February 2025 
    – open access publication
    Ophthalmic findings leading to diagnose chronic myeloid leukemia: A multimodal image case report
    Hoyos A et al. Eur J Ophthalmol, February 2025 (epub ahead of print)
    Proliferation inhibited by Genipin in human leukemia K562 cells:
    Involvement of uncoupling protein 2 in mitochondrial damage
    Zhou Y et al. World J Oncol, February 2025
    (epub ahead of print)
    – open access publication
    Asciminib in the treatment of chronic myeloid leukemia chronic phase – Review
    Costa A et al. Future Oncol, February 2025
    (epub ahead of print)
    CML with mutant ASXL1 showed decreased sensitivity to TKI treatment via upregulation of the ALOX5-BLTR Signaling Pathway
    Miyashita N et al. Cancer Sci, February 2025
    (epub ahead of print) 
    – open access publication
    A nomogram for predicting T315I-free survival in chronic-phase chronic myeloid leukemia patients: A multicentre retrospective study
    Hu SW et al. Sci Rep, February 2025
    – open access publication
     
    Introduction to a series of reflections on a quarter century of TKIs for CML
    Druker BJ. Blood, February 2025
    – open access publication
     
    Vodobatinib for patients with Philadelphia chromosome-positive chronic myeloid leukemia resistant or intolerant to multiple lines of previous therapy: an open-label, multicentre, phase 1 / 2 trial
    Cortes JE et al. Lancet Haematol, February 2025 (epub ahead of print)
     
    Blast-phase chronic myeloid leukemia presenting as early T-cell precursor acute lymphoblastic leukemia
    Shuyu E et al. Am J Clin Pathol, February 2025
     
    Inflammatory/immune adverse events in chronic myeloid leukemia patients during treatment with Bosutinib
    Agostani E et al. Cancer Med, February 2025 – open access publication
     
    Total psoriasis regression in a patient with chronic myeloid leukemia treated using Nilotinib
    Horňák T et al. Ann Hematol, February 2025
    (epub ahead of print) – open access publication
     
    Fibrosis and treatment-free remission in chronic myeloid leukemia
    Brailovski E et al. Br J Haematol, February 2025
    (epub ahead of print)
     
    BCR::ABL1 deep molecular response quantification and transcript type identification in chronic myeloid leukemia using a US Food and Drug Administration-approved droplet-based PCR assay
    Kockerols C et al. J Mol Diagn, February 2025 – open access publication
     
    Stopping bosutinib reverses bosutinib-induced elevation of serum creatinine in patients with chronic myeloid leukemia
    Abumiya M et al. Int J Hematol, February 2025
    (epub ahead of print) – open access publication
     
    Treatment-free remission outcomes in BCR::ABL1 digital PCR selected clinical cohort of chronic myeloid leukemia patients
    Kockerols C et al. Eur J Haematol, February 2025
    (epub ahead of print)
    – open access publication
     
    Challenges determining the best target duration of deep molecular response after which to attempt achieving therapy-free remission in chronic myeloid leukemia
    Gong X et al. Leukemia, February 2025
    (epub ahead of print)
    – open access publication
     
    Loss in overall and quality-adjusted life expectancy for patients with chronic-phase chronic myeloid leukemia
    Chen EY et al. Eur J Haematol, February 2025
    – open access publication
     
    January 2025
    Olverembatinib after failure of tyrosine kinase inhibitors, including ponatinib or asciminib: A phase 1b randomized clinical trial
    Jabbour E et al. JAMA Oncol, January 2025
    Design and fabrication of novel microfluidic-based droplets for drug screening on a chronic myeloid leukemia cell line
    Jaafari N et al. PLoS, January 2025
    – open access publication
    Real-world experience in the management of chronic myeloid leukemia patients focused on tyrosine kinase inhibitors intolerance and health-related quality of life
    Cho HJ et al. Acta Haematol, January 2025 (epub ahead of print)
    Exploring the significance of MDM2 gene promotes variants in chronic myeloid leukemia
    Fontecha MB et al. Leuk Res, January 2025 (epub ahead of print)
    Bosutinib for the treatment of CML – using it safely: a Podcast
    Lipton JH and Cortes JE. Target Oncol, January 2025 (epub ahead of print) 
    – open access publication 
    N-Degron PROTACs as a potential therapeutic approach for chronic myeloid leukemia
    Hohmann G & Eldeeb MA. Anticancer Agents Med Chem, January 2025
    (epub ahead of print)
    The evolution of treatment-free remission
    Hughes TP et al. Blood, January 2025
    (epub ahead of print) 
    Targeted degradation of SOS1 exhibits potent anticancer activity and overcomes resistance in KRAS-mutant tumors and BCR-ABL positive leukemia
    Luo Z et al. Cancer Res, January 2025
    – open access publication
    The recent advance of PROTACs targeting BCR-ABL for the treatment of chronic myeloid leukemia
    Qian Z et al. Bioorg Chem, January 2025
    (epub ahead of print) 

    Cotargeting of thioredoxin 1 and glutamate-cysteine ligase in both imatinib-sensitive and imatinib-resistant CML cells
    Sun X et al. Biochem Pharmacol, January 2025 (epub ahead of print)

    Cardiovascular toxicity induced by TKIs in patients with chronic myeloid leukemia: Are women and men different?
    Maduado C et al. ESC Heart Fail, January 2025
    (epub ahead of print) 
    – open access publication
    Lysosomal acid lipase A modulates leukemia stem cell response to venetoclax/tyrosine kinase inhibitor combination therapy in blast phase chronic myeloid leukemia
    Minhajuddin M et al. Haematologica, January 2025 – open access publication
    Efficacy and safety of the first-in-class STAMP inhibitor asciminib in patients with chronic myeloid leukemia – Review
    Ureshino H and Kimura S. Clin Lymphoma Myeloma Leuk, January 2025
    LIPA-frogging blast phase chronic myeloid leukemia: hopping over resistance with lysosomal targeting
    Quijada-Alamo M et al. Haematologica, January 2025  – open access publication
    Imatinib dose reduction after major molecular response in chronic-phase chronic myeloid leukemia
    Li Z et al. Cancer, January 2025
    – open access publication
    Single-cell proteo-transcriptomic profiling reveals altered characteristics of stem and progenitor cells in patients receiving cytoreductive hydroxyurea in early-phase chronic myeloid leukemia
    Komic H et al. Haematologica, January 2025 – open access publication
    Patient-reported outcomes in adults with tyrosine kinase inhibitor-resistant chronic myeloid leukemia receiving olverembatinib
    Yu L et al. Cancer, January 2025
    – open access publication
    High-throughput drug screening identifies SMAC mimetics as enhancers of NK cell toxicity in chronic myeloid leukemia
    Nygren PJ et al. Blood, January 2025 (epub ahead of print)
    Favorable transplantation outcome of patients with de novo chronic myeloid leukemia in blast phase (lymphoid and myeloid)
    Sasaki K. Cancer, January 2025
    Tyrosine kinase inhibitor therapy enhances stem cells profile and may contribute to survival of chronic myeloid leukemia stem cells
    Rocco S et al. J Clin Med, January 2025
    – open access publication
    Outcomes of pregnancy in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitors
    Kondo T et al. Cancer, January 2025
    – open access publication
    EZH2 modulates mRNA splicing and exerts part of its oncogenic function through repression of splicing factors in chronic myeloid leukemia
    Brunmeier R et al. Leukemia, January 2025
    (epub ahead of print)
    – open access publication
    Impact of first- and second-generation tyrosine kinase inhibitors on the development of graft-versus host disease in individuals with CML: A retrospective analysis on behalf of the Polish Adult Leukemia Group
    Giordano U et al. Biomedicines, January 2025
    - open access publication
     
    Clinical and prognostic significance of additional chromosomal abnormalities at diagnosis of chronic myeloid leukemia
    Mayer J et al. Am J Hematol, January 2025
    (epub ahead of print) 
    – open access publication
     
    Sustained treatment-free remission in two chronic myeloid leukemia patients after asciminib discontinuation: a report of two cases
    Yousefi A et al. Ann Hematol, January 2025
    (epub ahead of print) 
    – open access publication
     
    Asciminib versus bosutinib following two or more prior therapies in chronic myeloid leukemia: a plain language summary of the ASCEMBL study
    Szuber N et al. Future Oncol, January 2025
    (epub ahead of print) 
    – open access publication
     
    Discontinuation of tyrosine kinase inhibitor therapy and treatment free remission (TFR) in chronic myeloid leukemia: Successful achievement of TFR in more than two-third of patients in a real-world practice
    Aleem A et al. Clin Lymphoma Myeloma Leuk,
    January 2025
     
    Unusually indolent CML: a stable non-responder without complete cytogenetic remission for 30 years including 17 years on TKI therapy
    Shen Q et al. Leuk Lymphoma, January 2025
    (epub ahead of print)
     

    Find publications on pediatric CML here
    Find publications on COVID-19 and CML here
    Find CML publications from the emerging regions here

    CML Publications 2014-2024

    Access 2024 CML publications here

    Access 2023 CML publications here

    Access 2022 CML publications here

    Access 2021 CML publications here

    Access 2020 CML publications here

    Access 2019 CML publications here

    Access 2018 CML publications here

    Access 2017 CML publications here

    Access 2016 CML publications here

    Access 2015 CML publications here

    Access 2014 CML publications here


    Would you like to suggest an interesting paper or article? >> Please provide us with the details here and we will be happy to review your suggestion!

    Search for more publications on CML at PubMed.gov